Mindray Medical International Limited ( MR) Q4 2010 Earnings Call March 1, 2011 8:00 am ET Executives May Li – Director of Investor Relations Jie Liu – Chief Operating Officer Ronald Ede – Chief Financial Officer David Gibson – President of Mahwa Operations Xu Hang – Chairman and Co-Chief Exective Officer Li Xiting – President and Co-Chief Executive Officer Analysts Bin Li – Morgan Stanley Jinsong Du – Credit Suisse Katherine Lu – Oppenheimer & Company Richard Yeh – Citigroup Hongbo Lu – Piper Jaffray Jack Hu – Deutsche Bank Shaojing Tong – Bank of America-Merrill Lynch Yale Jen – Maxim Group Presentation Operator
Previous Statements by MR
» Mindray Medical CEO Discusses Q3 2010 Results - Earnings Call Transcript
» Mindray Medical International Limited Q2 2010 Earnings Call Transcript
» Mindray Medical International Ltd. Q1 2010 Earnings Call Transcript
» Mindray Medical International Ltd. Q4 2009 Earnings Call Transcript
Our management team will review fourth quarter and full year highlights as well as speak to the current financial and market environment in each of our major sales markets, after which management will be available to answer your questions.Before we continue, please note that this call will contain forward-looking statements made under the Safe Harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements involve inherent risks and uncertainties. As such, our results may be materially different from the views expressed today. A number of potential risks and uncertainties are outlined in our public filings with the SEC. Mindray does not undertake any obligation to update any forward-looking statements except as required under applicable law. I will now turn the call over to Mindray's Chief Operating Officer, Mr. Jie Liu. Jie Liu Thank you, May. Good morning and good evening, ladies and gentlemen. Thank you for joining us today for our 2010 fourth quarter and full year earnings results conference call. During today’s call, I will provide an overview of the company's overall operational performance. Our CFO, Ronnie Ede will review the detailed financial results. President of the North America Operations, David Gibson, will then discuss Mindray's operations in North American region. Before opening the call to questions, Ronnie will discuss the company’s 2011 outlook. First let me provide some operational highlights for the year. In 2010, we were encouraged to see recovery in certain geographies in which we operate, especially throughout the second half of the year. Overall, we achieved solid revenue growth of 11.1% year-over-year and $704.3 million. During the year, we maintained our focus on operational excellence and innovation. We increased our investments in the international delivery channel and our efforts yielded fruitful results. International sales have demonstrated solid growth of 20.3% year-over-year accelerating from 2010 level, of this emerging markets remained our key driver of growth and developed markets also recorded better than expected growth. In China, I expected weak government tender naturally impact our results, as a result. However, domestic sales growth was flat compared to 2009. I’ll go into detail during this call to provide perspectives on key international territory under the Chinese market growth.
R&D continues to be our focus in 2010. Our total R&D spending pre-capitalization for 2010 was a gain above 10% of total net revenues. As a result, we were able to launch 10 new products into the market, including one brand-new product, MRI systems, launching into the MRI market was a major product breakthrough for Mindray. We are extremely proud of this R&D achievement, optimistic about radiology aligned potentials for future growth. I will now turn the call over to Ronnie for financial details as well some fourth quarter highlights.Ronald Ede Thanks Jie. For the year, full-year 2010, we exclude the $8.6 million tax benefit recognized in the first quarter of 2010. Our non-GAAP net income grew 10.1% year-over-year to $162.3 million, exceeding our financial guidance. We have achieved healthy margins, our full-year non-GAAP gross margin was 57.7%, non-GAAP operating margin was 24.3% and non-GAAP net margin was 24.3%. During the year, we continue to make significant progress in North America operations, a number of significant R&D achievements will meet under the close collaborations between the China and U.S. team. Cost synergies will achieve for our U.S. entity, which has improved our overall gross margins. Other factors contributed to gross margin expansion with a shift towards both higher margin products and higher margin regions, as well as lower government tender sales in 2010. In 2010, we generated $147.8 million of net operating cash. We also completed an equity offering of approximately $150 million. This along with our strong operating cash flow generation, greatly helped to increase our cash reserve and strengthen our ability to further develop business. Read the rest of this transcript for free on seekingalpha.com